Pipeline
Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and autoimmune diseases. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
| Program | CAR/Antigen Target | Indication | Research | Preclinical | Phase 1 | Partner |
|---|---|---|---|---|---|---|
| Autoimmunity | ||||||
| FT819 (RMAT) |
CD19 | Systemic Lupus Erythematosus |
|
 |
||
| Systemic Sclerosis (SSc) |
|
|||||
| ANCA associated Vasculitius (AAV) |
|
|||||
| Idiopathis Inflammatory Myopathies (IIM) |
|
|||||
| FT839 (NxG) | CD19/CD38/CD20 | Pan-Indication w/o LLC |
|
|||
| FT522 | CD19/CD20 | Pan-Indication w/o LLC |
|
|||
| Oncology | ||||||
| FT825 | HER2/EGFR | Solid Tumor(s) |
|
 |
||
| Undisclosed | Undisclosed | Solid Tumor(s) |
|
|||
| FT836 (NxG) | MICA/B/EGFR/HER2 | Pan-Indication (Solid/Heme) w/o LCC |
|
|||
| FT836 (NxG) | CD19/CD38/BCMA/GPRC5D | Pan-Indication (Heme) w/o LCC |
|
|||
Autoimmunity
| Program | CAR/Antigen Target | Indication | Phase |
|---|---|---|---|
| FT819 (RMAT) | CD19 | Systemic Lupus Erythematosus | Ph 1 |
| Systemic Sclerosis (SSc) | Ph 1 | ||
| ANCA associated Vasculitius (AAV) | Ph 1 | ||
| Idiopathis Inflammatory Myopathies (IIM) | Ph 1 | ||
| FT839 (NxG) | Pan-Indication w/o LLC | CD19/CD38/CD20 | Ph 1 |
| FT522 | Pan-Indication w/o LLC | CD19/CD20 | Ph 1 |
Oncology
| Program | CAR/Antigen Target | Indication | Phase |
|---|---|---|---|
| FT825 | Solid Tumor(s) | HER2/EGFR | Ph 1 |
| Undisclosed | Solid Tumor(s) | Undisclosed | Ph 1 |
| FT836 (NxG) | Pan-Indication (Solid/Heme) w/o LCC | MICA/B/EGFR/HER2 | Ph1 |
| FT836 (NxG) | Pan-Indication (Heme) w/o LCC | CD19/CD38/BCMA/GPRC5D | Ph1 |
RMAT = FDA Regenerative Medicine Advanced Therapy (RMAT) recieved in SLE LCC = Lympho-conditioning chemotherapy NxG = Next-generation CAR T cell US rights to all products